For Rare Disorders, Best Shot At Showing Clinical Benefit Is Post-Market –FDA
Executive Summary
FDA is acknowledging that clinical benefit for patients with rare conditions may best be verified through post-marketing trials, given the difficulty of conducting clinical trials in those populations